Introduction
Histologically and biologically, endocrine cell tumors in the stomach are divided into two groups: (a) carcinoid tumor (CD), a low-grade malignancy, and (b) endocrine cell carcinoma (ECC), which is synonymous with smallcell carcinoma or poorly differentiated neuroendocrine carcinoma (PDNC), a high-grade malignancy [1, 2] . CD is characterized by trabecular, ribbon-like, or solid structures composed of uniformly small cells containing abundant amounts of cytoplasm with many neuroendocrine granules, including rare mitotic figures that generally behave in a low-grade malignant manner [1] [2] [3] [4] . Conversely, ECC is characterized by solid, large anastomosing trabecular structures composed of atypical cells larger than those of CD, with polymorphic nuclei, many mitotic figures, and aggressive biological behaviors, such as frequent vascular permeation and distant metastasis, even from an early stage [1, 2, 5] .
Iwafuchi et al. [5] reported that ECC frequently contains an adenocarcinomatous component, and proposed that ECC may be generated from a coexisting adenocarcinoma component. Whether or not ECC originates from adenocarcinoma precursor cells remains to be proven. A p53 mutation is well known to be the most common genetic alteration in ordinary gastric carcinomas [6] [7] [8] . However, no studies have reported on the genetic events contributing to the development of gastric ECC. In order to clarify the pathway of gastric ECC carcinogenesis, we analyzed the histopathological organization in a large number of cases, particularly in regard to the relationship between adenocarcinoma and ECC components. We also analyzed the concordance of the p53 mutational pattern between the two tissue components, using microdissection and direct sequencing techniques, this being the first time such a study has been done.
Subjects, materials, and methods
In this study, each ECC and CD diagnosis was established on the basis of the typical histological findings as described in the WHO blue book [1, 2] . These findings were confirmed by diffuse positivity for at least two well-known endocrine cell markers, including Grimelius' argyrophil stain, chromogranin A immunostain, and neuron-specific enolase immunostain.
The materials comprised 98 cases of endocrine cell tumor of the stomach, as follows: 68 ECC cases (15 early stage, 53 advanced) and 30 CD cases (all early stage), registered at the First Department of Pathology, Niigata University School of Medicine from 1980 through 2000. All tumors were surgically or endoscopically resected from 93 Japanese patients who had not had systemic adjuvant therapy; there were 68 patients with solitary ECC (54 men and 14 women; average age at surgery, 66.5 years) and 25 patients with CD (17 with sporadic CD and 8 with multifocal CD associated with type A gastritis; 11 men and 14 women; average age at endoscopic or surgical resection, 56.4 years). For the multifocal CD, we took 13 lesions from the 8 patients (2 CD lesions from each of 5 patients and 1 CD lesion from each of 3 patients). All tumors were fixed in 10% formalin solution immediately after resection, cut into 5-mmthick sections along the largest diameter of each tumor, and embedded in paraffin.
One to three representative blocks were serially sectioned (2-µm-thick), and stained with hematoxylineosin (H&E) for general histopathological analysis and some blocks were reserved for examination of endocrine cell markers: Grimelius' argyrophil stain, chromogranin A immunostain, and neuron-specific enolase immunostain were used as the endocrine cell markers.
p53 immunohistochemistry
For the p53 immunohistochemistry (IHC) study, 15 of the 30 CD cases and 34 (8 early stage and 26 advanced) of the 68 ECC cases were randomly selected. A serial section, following the endocrine cell marker section, was immunostained for p53 protein (PAb1801, mouse monoclonal, 1: 200; Oncogene Science, NY, USA), using the streptavidin-peroxidase complex method, as previously described [9] . Cells positive for p53 protein were defined as those with brownish nuclear staining, regardless of intensity. Expression of p53 protein was classified as follows: (Ϫ), negative; (ϩ), scattered positive cells; (ϩϩ), focal aggregates of positive cells; and (ϩϩϩ), positive cells distributed in most of the lesion. Staining patterns of (ϩϩ) and (ϩϩϩ) were considered to represent overexpression of p53 protein, consistent with our previous reports [9, 10] .
Microdissection and DNA preparation
Of the 34 ECC and 15 CD cases on which p53 IHC was performed, 15 ECC (1 early stage, 14 advanced) and 5 CD cases were selected for p53 gene analysis. One to four areas from the ECC components and one to three areas from the adenocarcinoma components, 60 areas in total, were sampled. Areas showing a histological shift from an adenocarcinoma component to an ECC component were excluded from the analysis. For CD, paraffin blocks were available for only 5 cases after repeated cutting, because of the rather small tumor size compared with ECC. One or two areas from each case were sampled, for 7 areas in total.
DNA extraction from paraffin sections was performed as follows: from each sample, five to ten serial unstained 10-µm-thick sections were dewaxed in xylene for 10min, rehydrated in 90% ethanol for 5 min, and then briefly stained with hematoxylin. Lesions were dissected under direct observation with a microscope at 40ϫ magnification, using sterilized, disposable 25-gauge needles (Terumo, Tokyo, Japan).
DNA was isolated using a DNA Isolator PS Kit (Wako, Osaka, Japan). Samples were precipitated with isopropyl alcohol and successively with 90% ethanol, dried, and then dissolved in 30µl sterilized water.
Polymerase chain reaction (PCR)
DNA was amplified using nested PCR. The target sequences of the p53 gene, exon 5 (codons 126-186), exon 6 (codons 187-224), exon 7 (codons 225-261), and exon 8 (codons 262-306) were each amplified independently with two sets of primers (Takara Shuzo, Kyoto, Japan) as previously described [10] . The first PCR product was used as the template for the second PCR, which was performed under the same conditions as the first. The product of the second PCR was electrophoresed for 20min on 4% agarose gel (NuSieve 3:1 Agarose; FMC BioProducts, Rockland, ME, USA). An amplified band was cut out from the gel and subsequently purified using a Mermaid Kit (Bio101, La Jolla, CA, USA).
Direct DNA sequencing
All products of the second PCR were sequenced directly, using an Auto Load Solid Sequencing Kit (Pharmacia Biotech, Uppsala, Sweden) and an automated laser fluorescent sequencer (ALF DNA Sequencer II; Pharmacia) equipped with ALF Manager Version 2.5. Each PCR product was sequenced at least twice in both sense and antisense directions to confirm the reproducibility of the results.
Statistical methods
We calculated 95% confidence intervals using Casella's procedure with the StatXact version 4 program (Cytel Software, Cambridge, MA, USA). (Fig. 1) . The remaining 6 cases demonstrated mixed-type adenocarcinoma, consisting of an undifferentiated part and a well-to moderately differentiated part; in all 6 cases, the latter part was located adjacent to the ECC component in the submucosal layer.
Results

Histopathological findings
No CD cases demonstrated adenocarcinoma components in the same tumor (0/30; 95% CI, 0%-11.6%). (Fig. 2) .
p53 IHC
None of the CD cases exhibited p53 overexpression (0/15; 95% CI, 0%-21.8%).
p53 gene analysis p53 DNA analysis was performed in 15 ECC cases; an identical p53 mutational pattern between the adenocarcinoma component and the ECC component was observed in 8 of these cases (cases 1-8). We identified three different mutational patterns in the ECC component in these 8 cases: 6 cases (cases 1-6) had a single mutational pattern, 1 (case 7) had double mutations (Fig. 3) , and 1 (case 8) had triple mutations. The latter two cases demonstrated other mutation(s) in addition to the identical mutation. Of these 8 cases, case 6 revealed a deletion of codon 209, while the other 7 cases demonstrated point mutations ( Table 2 ). In terms of the base-pair spectrum, 23 mutations in total were observed: 13 transitions (C to T, 4; G to A, 4; A to G, 3; T to C, 2), and 10 transversions (G to T, 5; C to A, 4; A to T, 1) ( Table 2) . Conversely, no mutations were detected in the adenocarcinoma component or the ECC component in 7 cases (cases 9-15): 3 cases (cases 9-11) demonstrated no evidence of p53 protein overexpression, and IHC revealed overexpression of both components in 4 cases (cases 12-15) ( Table 2) .
In contrast to the ECC cases, no p53 mutations were found in CD cases (0/5; 95% CI, 0%-52.2%).
Discussion
In the present study, 70.6% (48/68; 95% CI, 58.3%-81.0%) of ECC cases displayed adenocarcinoma components in the mucosa and/or submucosa, of which 87.5% (42/48; 95% CI, 74.8%-95.3%) were of well-to moderately differentiated type. Furthermore, 85.7% (95% CI, 71.5%-94.6%) of the differentiated adenocarcinoma components in the submucosal layer showed a shift to ECC components. In the mixed type adenocarcinoma, the differentiated part was located adjacent to the ECC component in the submucosa. These histopathological findings led us to presume that gastric ECC is derived from a preceding adenocarcinoma (particularly of differentiated type), and transforms into the ECC phenotype in the submucosa. As for the approximately 30% of ECC cases without an adenocarcinoma component, it is conceivable that, after or during histological transformation, the adenocarcinoma component may become necrotic and desquamate in association with ulcerative change, while the ECC component develops rapidly in the submucosa and deeper layers.
It is reported that p53 gene mutation is the most common event implicated in gastric carcinogenesis [6, 11] , in addition to an early genetic event, particularly However, 4 of 15 cases displayed p53 protein overexpression despite an absence of p53 gene mutation. There are two possible ways to account for this. One explanation is a false-positive IHC result; that is, posttranslational mechanisms stabilize the wild-type p53 by complex formation and lead to inactivation with mdm-2 products [13] or viral protein [14] . Another theory is that a p53 mutation may exist in exons other than 5 through 8. Further research needs to be conducted on such cases. In regard to the base-change spectrum, we found that 13 of the observed 23 point mutations (56.5%; 95% CI, 34.5%-76.8%) in ECC were of the transition type. This agrees with prior studies showing base transitions to be the most common point mutations, with a 50% to 91% frequency in gastric adenocarcinoma [7, 8, 11, 15, 16] .
Our histological findings and p53 gene analysis strongly support the hypothesis that most gastric ECCs are generated from precursor cell clones that occur in a preceding adenocarcinoma component (particularly of differentiated type) under the influence of p53 gene alteration, and transform into ECC in the submucosa during rapid clonal expansion. Vortmeyer et al. [17] investigated loss of heterozygosity (LOH) of PDNC, which is synonymous with ECC, in the large intestine. They found a concordance of LOH pattern between the PDNC component and the associated adenocarcinoma component; LOH of the APC, DCC, or p53 genes involved the same allele in both tissue components in four of five informative colorectal PDNCs. They postulated that, for a small number of examined cases, the colorectal PDNC and associated adenocarcinoma were derived from the same cell origin. This is consistent with our gastric ECC findings. However, it is reported that many gastric CD cases are formed by aggregations of endocrine cell micronests, predominantly composed of enterochromaffinlike cells, caused by the hypertrophic effect of hypergastrinemia, which is induced by extensive atrophic fundic gland mucosal change [18] . In the present study we could not find a CD case associated with the adenocarcinoma component, which presents little evidence for adenocarcinoma precursor cell-derived CD.
In addition, we did not find evidence of a CD case exhibiting p53 protein overexpression or p53 gene mutation, suggesting that CD development is independent of p53 gene alteration. Our results reveal that CD and ECC are two distinct neoplasms, not only with respect to histological features or biological behavior but also in terms of tumorigenic pathway.
In conclusion, it is highly possible that gastric ECC arises predominantly from endocrine precursor cell clones occurring in preceding adenocarcinoma (particularly differentiated type) components, and transforms into ECC during rapid clonal expansion under the influence of p53 gene alteration. also grateful to Dr. Kohei Akazawa, Department of Medical Informatics of Niigata University Medical Hospital, for his helpful advice on statistical procedures.
